Lupin, a global pharmaceutical company, has announced the launch of Ranluspec, its biosimilar ranibizumab, across Europe, excluding Germany. The product is being commercialised by Lupin's commercial partner, Sandoz, following approval from the European Commission for both vial and pre-filled syringe presentations.

The launch marks an expansion of treatment options for patients with retinal diseases and is expected to support access to high-quality biologic therapies across European markets.

Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). By targeting VEGF-A, the medicine is used in the management of several retinal and choroidal vascular conditions.

The approved indications for Ranluspec include neovascular age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy and choroidal neovascularisation.

Commenting on the launch, Thierry Volle, President, EMEA and Emerging Markets, Lupin, said the European introduction of Ranluspec supports the company's strategy of expanding access to high-quality biosimilars for patients with retinal and choroidal vascular diseases. He added that the collaboration with Sandoz would support the availability of the treatment across the region.

Dr. Cyrus Karkaria, President – Biotech Business, Lupin, said the launch further strengthens the company's biosimilars capabilities by combining its scientific expertise with biologics manufacturing capabilities. He also highlighted the company's focus on addressing unmet medical needs and supporting more sustainable healthcare systems through biosimilar development.

The European launch represents another development in Lupin's biosimilars business and its efforts to expand the availability of biologic treatment options across international markets.